Article | 2025 American Academy of Ophthalmology Annual Meeting
Sura Vec Shows Promise in NPDR
Two-year ALTITUDE data presented during AAO’s retina subspecialty day showed that the suprachoroidal anti-VEGF gene therapy achieved sustained DRSS gains with acceptable safety.







